The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The risk of thrombotic events in patients with MGUS: an analysis from the iStopMM trial
Sæmundur Rögnvaldsson, MD, PhD, University of Iceland, Reykjavik, Iceland, discusses a study investigating the risk of thrombotic events in patients who were screened for monoclonal gammopathy of undetermined significance (MGUS) in the iStopMM trial (NCT03327597). The study reveals a heightened susceptibility to venous thrombosis in this cohort, unrelated to increased M-protein concentration. Dr Rögnvaldsson proposes a hypothesis suggesting the existence of a pro-thrombotic protein interacting with M-protein, potentially triggering thrombosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
